COYA
What one share of Coya Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses.
Coya Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.40 |
|---|---|
| Profit | −$1.09 |
| Cash and investments | $1.84 |
| Book value | $1.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$1.89 | — | −$1.51 | — | $1.41 |
| 2022 | $0.00 | −$4.73 | — | −$2.79 | — | −$3.24 |
| 2023 | $0.59 | −$0.79 | — | −$1.10 | — | $2.47 |
| 2024 | $0.23 | −$0.98 | — | −$0.68 | — | $2.37 |
| 2025 | $0.47 | −$1.27 | — | −$0.64 | — | $2.06 |